PT Kalbe Farma Tbk's ROE % for the quarter that ended in Mar. 2026 was 17.29%. PT Kalbe Farma Tbk's PB Ratio for the quarter that ended in Mar. 2026 was 2.00.
PT Kalbe Farma Tbk's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 8.65%.
PT Kalbe Farma Tbk ROE % Adjusted to Book Value Related Terms
PT Kalbe Farma Tbk ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kalbe Farma Tbk ROE % Adjusted to Book Value Chart
FRA:LCLA vs LLY, JNJ, ABBV: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 8.65% mean?
PT Kalbe Farma Tbk (FRA:LCLA) has a ROE % Adjusted to Book Value of 8.65% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on PT Kalbe Farma Tbk and its competitors.
Is PT Kalbe Farma Tbk's ROE % Adjusted to Book Value too high?
PT Kalbe Farma Tbk's current ROE % Adjusted to Book Value is 8.65%. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's ROE % Adjusted to Book Value compare to LLY and JNJ?
PT Kalbe Farma Tbk's ROE % Adjusted to Book Value of 8.65% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on PT Kalbe Farma Tbk and its competitors. PT Kalbe Farma Tbk's current ROE % Adjusted to Book Value is 8.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.07, compared to a current price of €0.05 — trading 32.9% below its estimated fair value. The current ROE % Adjusted to Book Value is 8.65%. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current ROE % Adjusted to Book Value is 8.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.05 is trading 32.9% below its estimated GF Value™ of €0.07.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
ROE % Adjusted to Book Value: 8.65%
GF Value™: €0.07 vs. price of €0.05 (32.9% below fair value)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
